Arazi H and Gonzalez M .2017 .Nebivolol: Does the key lie in β3 agonism. Clin. Surg., 2(6) : 1660.
Badar VA,Hiware SK,Shrivastava MP,Thawani VR,Hardas MM .2011 .Comparison of nebivolol and atenolol on blood pressure, blood sugar and lipid profile in patients of essential hypertension. Indian J. Pharmacol., 43(4) : 437.
Bhosale VV,Inamdar SC,Karande VB,Burute SR,Murthy MB,Ghatak A .2014 .Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J. Clin. Diagn., Res, 8(6) : HC01-04.
Chung J,Han JK,Kim YJ,Kim CJ,Ahn Y,Chan Cho M,Chae SC,Chae IH,Chae JK,Seong IW,Yang HM .2017 .Benefit of Vasodilating β‐Blockers in Patients with acute myocardial infarction after percutaneous coronary intervention: nationwide multicenter cohort study. J. Am. Heart Assoc., 6(10) : e007063.
Coats A,Jain S A .2017 .Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage. J. Hum. Hypertens., 31(6) : 376-381.
Tsimihodimos V,Gonzalez-Villalpando C,Meigs JB,Ferrannini E .2018 .Hypertension and diabetes mellitus: Coprediction and time trajectories. Hypertension, 71(3) : 422-428.
do Vale GT,Ceron CS,Gonzaga NA,Simplicio JA,Padovan JC .2019 .Three generations of β-blockers: history, class differences and clinical applicability. Curr. Hypertens. Reviews, 15(1) : 22-31.
Kwon SW,Do JY,Hong GR,Kim BK,Hwang WM,Kim SH,Lee JY,Park SW,Kim DH,Benefit-Korea DH .2018 .P1871 Effect of nebivolol on lipid and metabolic profiles in Korean patients with hypertension: Result from Benefit-Korea study. Eur. Heart J., 39(Suppl 1) : ehy565-P1871.
Liu JY,Guo LN,Peng WZ,Jiang Y,Wang AL,Guo XM,Xu ZS .2020 .Efficacy and safety of nebivolol in hypertensive patients: A meta-analysis of randomized controlled trials. J. Int. Med. Res., 48(10) : 10.
Marketou M,Gupta Y,Jain S,Vardas P .2017 .Differential metabolic effects of beta-blockers: An updated systematic review of nebivolol. Curr. Hypertens. Rep, 19(3) : 22.
Marketou M,Gupta Y,Jain S,Vardas P .2017 .Differential metabolic effects of beta-blockers: An updated systematic review of nebivolol. Curr. Hypertens. Rep, 19(3) : 22.
Merugu PL,Bingi TC .2020 .Effect of nebivolol on microalbuminuria in hypertensive patients with or without type 2 diabetes mellitus. J. Pharmacol. Pharmacother., 11(1) : 13-18.
Olawi N,Krüger M,Grimm D,Infanger M,Wehland M M .2019 .Nebivolol in the treatment of arterial hypertension. Basic Clinical Pharmacol. Toxicol., 125(3) : 189-201.
Ozyıldız AG,Eroglu S,Bal U,Atar I,Okyay K,Muderrisoglu H K .2017 .Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J. Cardiovasc. Pharmacol. Ther., 22(1) : 65-70.
Petrie JR,Guzik TJ,Touyz RM .2018 .Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J. Cardiol., 34(5) : 575-584.
Saeedi P,Petersohn I,Salpea P,Malanda B,Karuranga S,Unwin N,Colagiuri S,Motala L,Ogurtsova AA,Shaw K,JE K .2019 .Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Prac, 157 : 107843.
Schmidt AC,Graf C,Scholze J .2007 .Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. Clin. Drug Investig, 27(12) : 841-849.
Unge T,Borghi C,Charchar F,Khan NA,Poulter NR,Prabhakaran D,Ramirez A,Schlaich M,Stergiou GS,Tomaszewski M,Wainford RD M .2020 .. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6) : 1334-1357.
Van Bortel LM .2010 .Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: A post-marketing surveillance study. Eur. Rev Med Pharmacol. Sci., 14(9) : 749-758.
Walczak-Gałęzewska M,Szulińska M,Miller-Kasprzak E,Pupek-Musialik D,Bogdański P .2018 .The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial. Medicine, 97(30) : 10.
Zheng Y,Ley SH,Hu FB .2018 .Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 14(2) : 88.